Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.34 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.34 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.34 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28271180 | 0.85 | ENPP3 (0.31) | — | |
| Pyridine SCHEMBL28259846 | 0.84 | NOTUM (0.41) | NPC1RAB9AATAD2NOTUMAR | |
| SCHEMBL637900 | 0.79 | RAB9A (0.42) | MAPTTP53PKMNPC1RAB9A | |
| SCHEMBL9315649 | 0.76 | RAB9A (0.45) | MAPTLMNATP53PKMNPC1 | |
| SCHEMBL2679544 | 0.76 | ENPP3 (0.47) | MAPTLMNATP53PKMNPC1 | |
| SCHEMBL12327638 | 0.76 | METAP2 (0.39) | — | |
| SCHEMBL8874568 | 0.76 | MAPT (0.45) | MAPTLMNATP53PKMNPC1 | |
| SCHEMBL69570 | 0.76 | — | — | |
| SCHEMBL5014126 | 0.76 | RAB9A (0.44) | MAPTLMNANPC1RAB9ANOTUM | |
| SCHEMBL7237023 | 0.75 | CYP2A6 (0.52) | MAPTLMNATP53CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3216798-A2 | KETOLIDE COMPOUNDS | Wockhardt Limited (IN) | 2017-09-13 | — | — | EP | disclosed |
| EP-2673285-B1 | KETOLIDE COMPOUNDS | WOCKHARDT LTD (IN) | 2017-07-19 | — | — | EP | disclosed |
| US-20160083412-A1 | KETOLIDE COMPOUNDS | WOCKHARDT LIMITED (IN) | 2016-03-24 | — | — | US | disclosed |
| CN-103384676-B | Ketolactone compounds | WOCKHARDT LTD. (IN) | 2016-02-03 | — | — | CN | disclosed |
| US-9175031-B2 | Ketolide compounds | WOCKHARDT LIMITED (IN) | 2015-11-03 | — | — | US | disclosed |
| US-20140005133-A1 | KETOLIDE COMPOUNDS | WOCKHARDT LIMITED (IN) | 2014-01-02 | — | — | US | disclosed |
| EP-2673285-A1 | KETOLIDE COMPOUNDS | Wockhardt Limited (IN) | 2013-12-18 | — | — | EP | disclosed |
| CN-103384676-A | Ketolactone compounds | WOCKHARDT LTD | 2013-11-06 | — | — | CN | disclosed |
| WO-2012076989-A1 | KETOLIDE COMPOUNDS | WOCKHARDT LIMITED (IN) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083412-A1 | KETOLIDE COMPOUNDS | AKR1C3, AKR1D1, AKR1C1 | MAPT 3391/4885LMNA 4283/4885TP53 2431/4885 |
| US-20140005133-A1 | KETOLIDE COMPOUNDS | AKR1C3, AKR1D1, AKR1C1 | MAPT 3432/4885LMNA 4118/4885TP53 2295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.